Nurix Therapeutics (NASDAQ:NRIX) Given New $34.00 Price Target at JPMorgan Chase & Co.

Nurix Therapeutics (NASDAQ:NRIX) had its target price upped by JPMorgan Chase & Co. from $31.00 to $34.00 in a research note published on Monday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Barclays boosted their price target on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an overweight rating in a research report on Monday. Royal Bank of Canada upped their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an outperform rating in a research report on Friday, July 12th. Robert W. Baird lifted their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an outperform rating in a report on Thursday, April 11th. Piper Sandler restated an overweight rating and set a $35.00 price target on shares of Nurix Therapeutics in a report on Wednesday, June 5th. Finally, Stephens initiated coverage on shares of Nurix Therapeutics in a research note on Tuesday, May 14th. They set an overweight rating and a $20.00 price objective for the company. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $25.82.

Nurix Therapeutics Trading Down 4.6 %

Shares of NRIX opened at $21.77 on Monday. Nurix Therapeutics has a 12-month low of $4.22 and a 12-month high of $24.38. The company has a market capitalization of $1.07 billion, a PE ratio of -7.46 and a beta of 2.22. The business’s 50 day moving average is $17.84 and its 200 day moving average is $13.90.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Equities research analysts predict that Nurix Therapeutics will post -2.84 earnings per share for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60. Following the completion of the sale, the insider now directly owns 19,838 shares of the company’s stock, valued at approximately $412,828.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Christine Ring sold 5,760 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $20.81, for a total transaction of $119,865.60. Following the transaction, the insider now directly owns 19,838 shares in the company, valued at $412,828.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Houte Hans Van sold 3,499 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total value of $44,892.17. Following the sale, the chief financial officer now directly owns 68,333 shares in the company, valued at approximately $876,712.39. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,549 shares of company stock worth $271,888. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NRIX. Massachusetts Financial Services Co. MA grew its position in Nurix Therapeutics by 248.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 142,146 shares of the company’s stock worth $1,467,000 after purchasing an additional 101,320 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Nurix Therapeutics by 80.9% during the fourth quarter. Trexquant Investment LP now owns 159,318 shares of the company’s stock valued at $1,644,000 after buying an additional 71,252 shares during the last quarter. Affinity Asset Advisors LLC increased its position in shares of Nurix Therapeutics by 176.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after acquiring an additional 440,112 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Nurix Therapeutics by 351.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after acquiring an additional 4,367 shares during the last quarter. Finally, ARK Investment Management LLC lifted its position in Nurix Therapeutics by 23.2% during the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock worth $32,972,000 after acquiring an additional 601,952 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.